Antitumor potential of cisplatin loaded into SBA-15 mesoporous silica nanoparticles against B16F1 melanoma cells: in vitro and in vivo studies

• Published in: Journal of inorganic biochemistry Vol. 217; p. 111383
• Main Authors: Drača, Dijana, Edeler, David, Saoud, Mohamad, Dojčinović, Biljana, Dunđerović, Duško, Đmura, Goran, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Kaluđerović, Goran N.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2021
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Autophagy; Autophagy - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Cisplatin; Cisplatin - pharmacology; Cisplatin - therapeutic use; Cytotoxicity; Drug carrier; Drug Carriers - chemistry; Female; G2 Phase Cell Cycle Checkpoints - drug effects; Melanoma, Experimental - drug therapy; Melanoma, Experimental - pathology; Mice; Mice, Inbred C57BL; Nanoparticles - chemistry; Nitric Oxide - metabolism; Porosity; SBA-15; Silicon Dioxide - chemistry; NO; SBA-15|CP; Drug carrier; Cytotoxicity; MTT; Autophagy; DHR; FBS; RPMI-1640; SBA-15; PBS; DAF FM; DAPI; CFSE; B16F1; MCM-41; EDTA; CP; Cisplatin; AO; SA-β-Gal; CV; ROS; PI; Apoptosis; SBA-15p

CP (cisplatin) and mesoporous silica SBA-15 (Santa Barbara amorphous 15) loaded with CP (→SBA-15|CP) were tested in vitro and in vivo against low metastatic mouse melanoma B16F1 cell line. SBA-15 only, as drug carrier, is found to be not active, while CP and SBA-15|CP revealed high cytotoxicity in l...